| Literature DB >> 35695276 |
Sakari Pakarinen1, Pirita Varpe1, Anu Carpelan1, Mari Koivisto2, Heikki Huhtinen1.
Abstract
OBJECTIVE: The follow-up of the increasing number of cancer survivors threatens to overload the health care system. While short message system (SMS)-based communication is widely used in other areas of the health care system, there are no studies of its appliance in cancer surveillance. The aim of the current study was to analyze the acceptability, convenience and impact of a novel mobile phone messaging -based system (Mobile-CEA) on health personnel contacts in patients with colorectal cancer (CRC) during 2 years of follow-up.Entities:
Keywords: CEA; colorectal cancer; mobile phone; short message system; surveillance
Mesh:
Year: 2022 PMID: 35695276 PMCID: PMC9209784 DOI: 10.1177/10732748221102780
Source DB: PubMed Journal: Cancer Control ISSN: 1073-2748 Impact factor: 2.339
CRC Surveillance Scheme in Turku University Hospital.
| History and Physical examination | S-CEA and P-Hb | Colonoscopy | Body CT | |
|---|---|---|---|---|
| Standard surveillance | every 6 month for the first 2 years, then annually for 3 years | every 6 months for the first 2 years then annually for 3 years | 2–3 years after resection if preoperative was clear, then every 5 years | 12 and 24 months in stage III-IV, then selectively |
| Mobile-CEA surveillance | Only patients with digitally examinable rectal anastomosis every 6 months for the first 2 years, then annually for 3 years | every 6 months for the first 2 years then annually for 3 years (mobile application) | 2-3 years after resection if preoperative was clear,then every 5 years | 12 and 24 months in stage III-IV, then selectively |
Patient Characteristics.
| Variable | Standard Surveillance (n 30) | Mobile-CEA Surveillance (n 22) |
|
|---|---|---|---|
| Age median (min-max) | 73 (51.0–85.0) | 70 (48.2–82.4) | .09
|
| Sex M/F (n) | 11/19 | 10/12 | .52
|
| ASA classification 1/2/3 (n) | 1/11/18 | 0/9/13 | 1.0
|
| BMI median (min.-max) | 26,0 (18.0–38.0) | 26,0 (20.0–51.0) | .77
|
| Adjuvant chemotherapy (n) | 1 | 2 | .57
|
| Colon/rectum (n) | 22/8 | 13/9 | .28
|
| Stage I/II/III (n) | 11/18/1 | 13/7/2 | .11
|
| Preoperative CEA >4,6 ug/l (n) | 10 | 7 | .91
|
a Wilcoxon Two-Sample test.
b Chi-Square.
c Fischer's exact test.
Figure 1.Number of contacts between the standard and Mobile-CEA groups (n/%) in 2-year surveillance.
Figure 2.The reasons for contacts in the Mobile-CEA surveillance group.
Mobile-CEA Group Patient Satisfaction Questionnaire and Results (n = 22).
| Question | Yes | No |
|---|---|---|
| Did you get enough information about the Mobile-CEA surveillance? | 21 (95, 5%) | 1 (4, 5%) |
| Are you satisfied in the Mobile-CEA surveillance method? | 22 (100%) | |
| Did you get enough personal contact from the medical staff during surveillance? | 20 (90, 9%) | 2 (9, 1%) |
| Was it easy to reach personnel if you had any questions or problems during surveillance? | 20 (90, 9%) | 2 (9, 1%) |